北京大学学报(医学版) ›› 2018, Vol. 50 ›› Issue (5): 805-810. doi: 10.19723/j.issn.1671-167X.2018.05.007

• 论著 • 上一篇    下一篇

乳头状肾细胞癌合并癌栓患者的临床病理分析

丁振山,邱敏,徐梓程,肖若陶,葛力源,马潞林△   

  1. (北京大学第三医院泌尿外科, 北京100191)
  • 出版日期:2018-10-18 发布日期:2018-10-18
  • 通讯作者: 马潞林 E-mail:malulin@medmail.com.cn

Clinicopathological analysis of patients with papillary renal cell carcinoma complicated by tumor thrombus

DING Zhen-shan,QIU Min,XU Zi-cheng,XIAO Ruo-tao,GE Li-yuan,MA Lu-lin△   

  1. (Department of Urology, Peking University Third Hospital, Beijing 100191, China)
  • Online:2018-10-18 Published:2018-10-18
  • Contact: MA Lu-lin E-mail:malulin@medmail.com.cn

摘要: 目的:探讨乳头状肾细胞癌(papillary renal cell carcinoma,PRCC)以及PRCC合并癌栓患者的临床病理特点、治疗及预后。方法:回顾性分析单中心2012年1月至2017年10月收治的75例PRCC的病例,其中男性55例,女性20例,年龄24~82岁,合并癌栓的患者16例,所有病例均为手术患者,病理诊断明确,随访数据完整。总结分析PRCC以及合并癌栓患者的临床病理特点、预后及影响因素。结果:75例患者平均年龄(56.05±11.59)岁,平均体重指数(26±3) kg/m2,肿瘤平均最大径(5.17±3.85) cm,肿瘤最大径是否大于7 cm(69.6%vs.94.4%,P<0.001),有无淋巴结转移(<38%vs.98%,P<0.001)、有无肾上腺转移(0% vs.95.3%,P<0.001)、有无肺转移(0% vs.90.7%,P<0.001)、是否合并癌栓(<66.4%vs.93.5%,P<0.001)对PRCC患者3年生存率的影响差异有统计学意义。本研究患者中,合并癌栓患者16例,16例患者均为2型PRCC。合并癌栓的患者在有无伴随症状(62.5% vs. 22%,P=0.005)、肿瘤最大径(68.8% vs.13.3%,P<0.001)、有无肾上腺转移(18.8% vs.0.02%, P=0.029)、有无肺转移(18.8% vs.0%,P=0.008)、核分级(P<0.001)以及病理分型(100% vs.44.1%,P<0.001)方面,与不合并癌栓患者的差异有统计学意义。结论:肿瘤最大径、淋巴结转移、肾上腺转移、肺转移、是否合并癌栓是PRCC患者3年生存率的影响因素;本研究中合并癌栓的PRCC患者均为2型,肿瘤直径更大、核分级更高、更容易发生远处转移。

关键词: 乳头状肾细胞癌, 癌栓, 生存率

Abstract: Objective: To investigate the clinicopathological features,treatment and prognosis of patients with papillary renal cell carcinoma (PRCC) and PRCC-complicated with tumor thrombus. Me-thods: Single center retrospective analysis of 75 patients with PRCC treated from January 2012 to October 2017 was performed. There were 55 males and 20 females at an age range of 24-82 years. Sixteen PRCC patients were complicated with tumor thrombus. All the patients were with a surgery and had clear pathological diagnosis and detailed follow-up data. The clinicopathological features,prognosis and influencing factors of the patients with PRCC and PRCC complicated with tumor thrombus were analyzed and summarized. Results: The average age of the 75 patients was(56.05±11.59)years,the average body mass index (BMI) was (26±3) kg/m2, and the average tumor maximum diameter was(5.17±3.85)cm. There were significant differences between tumor maximum diameter larger than 7 cm and less than 7 cm (69.6% vs. 94.4%, P<0.001), lymph node metastasis and no lymph node metastasis (<38% vs. 98%, P<0.001), adrenal metastasis and no adrenal metastasis (0% vs. 95.3%, P<0.001), pulmonary metastasis and no pulmonary metastasis (0% vs.90.7%, P<0.001), complicated with and without tumor thrombus (<66.4% vs. 93.5%, P<0.001) on the effect of 3-year survival rate of the PRCC patients. In this study, there were 16 patients with type 2 PRCC complicated with tumor thrombus. There were significant differences in concomitant symptoms (62.5% vs. 22.0%, P=0.005), maximum tumor diameter (68.8% vs.13.3%, P<0.001), adrenal metastasis (18.8% vs. 0.02%, P=0.029), pulmonary metastasis (18.8% vs. 0%, P=0.008), nuclear grade (P<0.001) and pathological type (100% vs. 44.1%, P<0.001) between the PRCC patients with  and  without tumor thrombus. Conclusion: There were significant differences in tumor diameter,lymph node metastasis,adrenal metastasis,pulmonary metastasis,pathological type,nuclear grade and tumor thrombus in the effect of the 3year survival rate of PRCC patients. PRCC patients with tumor thrombus were more commonly suffered from type 2 PRCC, for whom the tumor diameter was larger,the nuclear grade was higher,and the distance metastasis happened more easily.

Key words: Papillary renal cell carcinoma, Tumor thrombus, Survival rate

中图分类号: 

  • R737.1
[1] 刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报(医学版), 2024, 56(4): 624-630.
[2] 吴美辰,许桐楷,安伟,刘中宁,姜婷. 后牙高嵌体和贴面修复的4年临床随访[J]. 北京大学学报(医学版), 2024, 56(1): 88-92.
[3] 兰东,刘茁,李宇轩,王国良,田晓军,马潞林,张树栋,张洪宪. 根治性肾切除和静脉癌栓取出术大出血的危险因素[J]. 北京大学学报(医学版), 2023, 55(5): 825-832.
[4] 刘茁,朱国栋,唐世英,洪鹏,赵勋,张启鸣,李丽伟,彭冉,陈志刚,王滨帅,张丽,杨飞龙,葛力源,孙争辉,张树栋,王国良,田晓军,张洪宪,马潞林. 外科手术治疗年龄≥75岁的高龄肾细胞癌合并静脉癌栓患者的临床经验[J]. 北京大学学报(医学版), 2022, 54(4): 774-778.
[5] 博尔术,洪鹏,张宇,邓绍晖,葛力源,陆敏,李楠,马潞林,张树栋. 乳头状肾细胞癌的临床病理特征和预后分析[J]. 北京大学学报(医学版), 2022, 54(4): 615-620.
[6] 赵勋,颜野,黄晓娟,董靖晗,刘茁,张洪宪,刘承,马潞林. 癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响[J]. 北京大学学报(医学版), 2021, 53(4): 665-670.
[7] 毕海,黄毅,马潞林,陆敏,张树栋,张洪宪. 3例肾尤文肉瘤合并下腔静脉癌栓的诊治[J]. 北京大学学报(医学版), 2020, 52(5): 985-989.
[8] 田晓军,邱敏,刘茁,肖若陶,黄毅,王国良,侯小飞,张树栋,庄申榕,马潞林. 微创手术治疗肾癌合并Mayo 0~2级静脉癌栓的单中心研究[J]. 北京大学学报(医学版), 2018, 50(6): 1053-1056.
[9] 曾鸿,容晓莹,张小青,郭向阳. 肾癌伴下腔静脉癌栓手术中应用回收式自体输血联合白细胞滤器2例[J]. 北京大学学报(医学版), 2017, 49(4): 736-739.
[10] 刘茁,马潞林,田晓军,王国良,侯小飞,张树栋,邓绍晖. 肾癌根治性切除加癌栓取出术治疗Mayo Ⅲ级下腔静脉癌栓的手术技术及临床经验[J]. 北京大学学报(医学版), 2017, 49(4): 597-602.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!